Managing Safety in Personalised Clinical Trials for Bipolar I Disorder: Lithium-Based Treatment

Learn how Aixial ensures patient safety and regulatory compliance in personalised lithium-based clinical trials for bipolar I disorder.

Bipolar I disorder is a complex psychiatric condition in which treatment response and safety profiles can vary widely from one patient to another. Clinical trials in this area require particularly strong pharmacovigilance, combining regulatory rigor with sound clinical judgment to support personalised treatment strategies.

Date: 14 January 2026 | Ref: CS005

At Aixial, we were responsible for the full pharmacovigilance oversight of this personalised lithium clinical trial, supporting the sponsor throughout the study by delivering robust, responsive, and inspection-ready pharmacovigilance services. This case study illustrates our ability to manage complex safety events while safeguarding patient safety, ensuring regulatory compliance, and supporting uninterrupted trial conduct.

Clinical trial overview

Clinical setting: Interventional clinical trial focused on optimising individual lithium treatment response in patients with bipolar I disorder
Population: Adult patients diagnosed with bipolar I disorder
Number of participants: 350 patients
Approach: Personalised evaluation of treatment exposure and safety
Safety framework: Continuous SAE monitoring and expedited SUSAR reporting

Challenges and mitigations in safety management

During the conduct of the trial, a serious and unexpected safety event was identified, requiring immediate pharmacovigilance assessment. The situation involved exposure beyond protocol-defined treatment conditions in a patient with psychiatric comorbidities and multiple concomitant medications.

The main challenge was to rapidly and accurately assess the regulatory impact of the event while distinguishing individual patient-related factors from potential treatment-related risks. This assessment was further complicated by differences in protocol requirements and safety reporting obligations between EU and non-EU countries, requiring careful regulatory interpretation and coordination across regions.

Aixial pharmacovigilance approach

Our pharmacovigilance team implemented a structured and proactive safety response in line with international clinical trial requirements, ICH-GCP. This included:

Rapid case intake, validation, and medical review using our pharmacovigilance Safety database
Assessment of seriousness, causality, and expectedness based on the Reference Safety Information
Close collaboration with clinical and site teams to ensure accurate and complete clinical context
Preparation and submission of an expedited 7 day SUSAR within regulatory timelines
Ongoing safety follow-up to ensure data completeness, traceability, and inspection readiness

Throughout the process, patient safety remained the top priority, while enabling informed clinical decision-making and maintaining trial momentum.

Key outcomes

Timely submission of the SUSAR in full compliance with regulatory requirements
Proven ability to manage high-risk safety situations in psychiatric clinical trials
Strong expertise in expedited safety reporting and regulatory interpretation
Pharmacovigilance support tailored to personalised treatment strategies
Reliable performance under pressure in complex and sensitive trial environments

Why this matters

Clinical trials using personalised treatment approaches present increased safety and regulatory complexity. For sponsors developing therapies in complex therapeutic areas, experienced pharmacovigilance is critical. This case highlights how Aixial goes beyond meeting timelines, providing the insight, structure, and clinical understanding needed to protect patients, support regulatory confidence, and keep clinical trials moving forward.

Why choose Aixial for Bipolar I Disorder clinical trials?

Clinical trials in this area require particularly strong pharmacovigilance, combining regulatory rigor with sound clinical judgment to support personalised treatment strategies.

Expertise in Complex Therapeutic Areas: Bipolar I disorder trials involve high variability in patient response and comorbidities. Our team understands these nuances and applies tailored pharmacovigilance strategies
Rapid, Compliant Safety Response: We deliver inspection-ready pharmacovigilance processes, ensuring expedited SUSAR reporting and uninterrupted trial conduct, even under pressure
Global Regulatory Confidence: Navigating EU and non-EU safety reporting requirements can be challenging. We provide seamless coordination across regions, reducing compliance risk for sponsors
Patient Safety as Priority: Every action we take safeguards patients while enabling informed clinical decisions, protecting both trial integrity and sponsor reputation
Proven Track Record: Our ability to manage unexpected, high-risk safety events demonstrates reliability and resilience in complex trial environments

Partnering with Aixial means your clinical trial benefits from a proactive, structured, and expert-driven pharmacovigilance approach – critical for success in personalised medicine and psychiatric clinical trials.